Addition of bone marrow aspirate to TCP show no benefit in radiographic outcomes .
This report has been verified
by one or more authors of the
original publication.
Ultraporous B-Tricalcium Phosphate Alone or Combined with Bone Marrow Aspirate for Benign Cavitary Lesions: Comparison in a Prospective Randomized Clinical Trial
J Bone Joint Surg Am. 2013 Jan 16;95(2):158-66. doi: 10.2106/JBJS.K.0018155 patients were randomized to evaluate the healing of cavity defects filled with ultraporous B-tricalcium phosphate (TCP) versus TCP and bone marrow aspirate (TCP/BM). Patients with a benign bone lesion received either TCP or TCP/BM and were assessed at 24 months. Results revealed that while significant improvements in radiographic parameters were reported in both groups, the addition of BM did not provide any noticeable benefit.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
